Covis Pharmaceuticals, Inc Named US Distributor For Five Additional Products
CARY, N.C., April 5, 2013 /PRNewswire/ -- Covis Pharmaceuticals, Inc. announced an agreement today to distribute Nilandron ® (nilutamide), Plaquenil ® (hydroxychloroquine), Rilutek ® (riluzole), Uroxatral ® (alfuzosin hydrochloride) and Kayexalate ® (sodium polystyrene sulfate) in the United States.The products cover a broad array of treatments and disease states: Nilandron is used to treat prostate cancer; Plaquenil is an anti-malarial drug; Rilutek treats amyotrophic lateral sclerosis; Uroxatral is used to treat Benign Prostatic Hyperplasia (BPH); and, Kayexalate is prescribed to remove dangerously high levels of potassium in the blood. With the addition of these products, Covis Pharmaceuticals, Inc. will be distributing 11 brands in the United States. As part of their mission to ensure availability and access to all products, Covis will continue to offer a patient assistance program
"This agreement underscores our commitment to provide patients with a continuous supply of safe and efficacious therapeutic solutions," said Bill Collins, Chief-Executive-Officer of Covis. "These additional products will allow Covis to broaden our portfolio with consistent, top quality branded pharmaceuticals."
The company's current product portfolio includes Lanoxin ® (digoxin) Tablets, Lanoxin ® (digoxin) IV, Parnate ® (tranylcypromine sulfate tablets), Zantac ® (ranitidine hydrochloride) Injection, Fortaz ® (ceftazidime for injection) and Zinacef ® (cefuroxime for injection). For full prescribing information on these Covis products, including boxed warnings for Parnate ®, please visit www.covispharma.com or contact the Company at 919-535-3049. For full prescribing information on Nilandron Tablets, Plaquenil Tablets, Rilutek Tablets, Uroxatral Tablets, and Kayexalate Powder, including boxed warnings for Nilandron and Plaquenil, please visit http://dailymed.nlm.nih.gov.
Fortaz®, Zinacef®, Lanoxin®, and Parnate® are registered trademarks of the GlaxoSmithKline group of companies. Zantac® is a registered trademark of Boehringer Ingelheim Pharmaceuticals, Inc., used under license.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts